133 related articles for article (PubMed ID: 38820045)
21. Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Wang S; Liang Y; Chang W; Hu B; Zhang Y
Med Sci Monit; 2018 Apr; 24():1912-1923. PubMed ID: 29605826
[TBL] [Abstract][Full Text] [Related]
22. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
So JY; Lin JJ; Wahler J; Liby KT; Sporn MB; Suh N
PLoS One; 2014; 9(9):e107616. PubMed ID: 25229616
[TBL] [Abstract][Full Text] [Related]
23. Indolocarbazole alkaloid Loonamycin A inhibits triple-negative breast cancer cell stemness and Notch signalling.
Xue W; Li W; Yu Y; Zhang B; Wang Y; Zhou L; Chen Z; Wang L; Ge H; Xu Q; Shen Y
J Pharm Pharmacol; 2023 Apr; 75(4):523-532. PubMed ID: 36861187
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer.
Jaiswal A; Murakami K; Elia A; Shibahara Y; Done SJ; Wood SA; Donato NJ; Ohashi PS; Reedijk M
Proc Natl Acad Sci U S A; 2021 Sep; 118(38):. PubMed ID: 34518219
[TBL] [Abstract][Full Text] [Related]
25. Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures.
Locatelli M; Curigliano G
Curr Opin Oncol; 2017 Nov; 29(6):411-427. PubMed ID: 28914645
[TBL] [Abstract][Full Text] [Related]
26. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Nasser F; Moussa N; Helmy MW; Haroun M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
[TBL] [Abstract][Full Text] [Related]
27. Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer.
Marini W; Wilson BE; Reedijk M
DNA Cell Biol; 2023 Feb; 42(2):73-81. PubMed ID: 36579947
[TBL] [Abstract][Full Text] [Related]
28. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical significance of androgen receptor in triple negative breast cancer.
Luo X; Shi YX; Li ZM; Jiang WQ
Chin J Cancer; 2010 Jun; 29(6):585-90. PubMed ID: 20507730
[TBL] [Abstract][Full Text] [Related]
30. A functional Notch-survivin gene signature in basal breast cancer.
Lee CW; Simin K; Liu Q; Plescia J; Guha M; Khan A; Hsieh CC; Altieri DC
Breast Cancer Res; 2008; 10(6):R97. PubMed ID: 19025652
[TBL] [Abstract][Full Text] [Related]
31. Triple-negative breast cancer: clinical features and patterns of recurrence.
Dent R; Trudeau M; Pritchard KI; Hanna WM; Kahn HK; Sawka CA; Lickley LA; Rawlinson E; Sun P; Narod SA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4429-34. PubMed ID: 17671126
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
33. Prognostic values of Notch receptors in breast cancer.
Xu J; Song F; Jin T; Qin J; Wu J; Wang M; Wang Y; Liu J
Tumour Biol; 2016 Feb; 37(2):1871-7. PubMed ID: 26323259
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
[TBL] [Abstract][Full Text] [Related]
35. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
[TBL] [Abstract][Full Text] [Related]
36. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
[TBL] [Abstract][Full Text] [Related]
38. Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.
Hossain F; Sorrentino C; Ucar DA; Peng Y; Matossian M; Wyczechowska D; Crabtree J; Zabaleta J; Morello S; Del Valle L; Burow M; Collins-Burow B; Pannuti A; Minter LM; Golde TE; Osborne BA; Miele L
Front Oncol; 2018; 8():575. PubMed ID: 30564555
[TBL] [Abstract][Full Text] [Related]
39. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
[TBL] [Abstract][Full Text] [Related]
40. The clinical significance and biological function of olfactomedin 4 in triple negative breast cancer.
Xiong B; Lei X; Zhang L; Fu J
Biomed Pharmacother; 2017 Feb; 86():67-73. PubMed ID: 27939521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
